Our study provides the first evidence that Rad21, and possibly cohesin and their associated genes, represent a new class of novel total body radiation response gene(s) in mammals, the characterisation of which has important implications for patient-tailored cancer therapy and modulating normal tissue responses to clinical RT. This evidence concerns the gene RAD21 and cancer.